US EditionPublished • loading... • Updated
Nirsevimab Dramatically Reduces RSV Hospitalizations in Infants: 2024–2025 Cohort Study
Summary by healtheconomics.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Nirsevimab Dramatically Reduces RSV Hospitalizations in Infants: 2024–2025 Cohort Study
A recent retrospective cohort study examined the effectiveness of nirsevimab in preventing respiratory syncytial virus (RSV) hospitalizations among infants during the 2024–2025 RSV season. Using anonymized data from the Epic Systems Cosmos dataset, researchers analyzed outcomes for 409,723 infants born between February 2024 and January 2025. After exclusions, nearly half (47.5%) of the infants received nirsevimab. The study found that only 0.4% …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
